MIM
MXCT icon

MetLife Investment Management’s MaxCyte MXCT Stock Holding History

MetLife Investment Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,200
Closed -$23.6K – 2822
2025
Q4 		$23.6K Sell
15,200
-27,392
-64% -$43.8K ﹤0.01% 2773
2025
Q3 		$67.3K Sell
42,592
-17,418
-29% -$30.3K ﹤0.01% 2767
2025
Q2 		$131K Buy
60,010
+9
+0% +$22 ﹤0.01% 2404
2025
Q1 		$164K Sell
60,001
-982
-2% -$3.87K ﹤0.01% 2301
2024
Q4 		$254K Hold
60,983
– – ﹤0.01% 2177
2024
Q3 		$237K Hold
60,983
– – ﹤0.01% 2200
2024
Q2 		$239K Buy
60,983
+13,315
+28% +$57.3K ﹤0.01% 2136
2024
Q1 		$200K Hold
47,668
– – ﹤0.01% 2203
2023
Q4 		$224K Hold
47,668
– – ﹤0.01% 2178
2023
Q3 		$149K Hold
47,668
– – ﹤0.01% 2366
2023
Q2 		$219K Sell
47,668
-8,456
-15% -$38.9K ﹤0.01% 2215
2023
Q1 		$278K Hold
56,124
– – ﹤0.01% 2014
2022
Q4 		$306K Hold
56,124
– – ﹤0.01% 1970
2022
Q3 		$365K Hold
56,124
– – ﹤0.01% 1869
2022
Q2 		$265K Hold
56,124
– – ﹤0.01% 2113
2022
Q1 		$392K Buy
56,124
+20,012
+55% +$137K ﹤0.01% 1931
2021
Q4 		$368K Buy
+36,112
New +$388K ﹤0.01% 1673

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

MetLife Investment Management's MXCT Position: Q1 2026 in Review

MetLife Investment Management sold out of MaxCyte (MXCT) in Q1 2026, closing a stake of 15,200 shares — an estimated $23.6K sold.

MetLife Investment Management first reported a position in MXCT in Q4 2021 and held it in 17 quarters. The position peaked at $392K in Q1 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • MetLife Investment Management reported no remaining MaxCyte position as of Q1 2026 after selling out during the quarter.
  • MetLife Investment Management sold 15,200 MaxCyte shares in Q1 2026, an estimated $23.6K.
  • MetLife Investment Management first reported a position in MaxCyte in Q4 2021 and held it in 17 quarters.
  • MetLife Investment Management's MaxCyte position peaked at $392K in Q1 2022.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.